Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence- based management of side effects. BJU Int 2013;111:543-548.Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013;111:543-548....
Androgen deprivation therapy (ADT), a treatment for prostate cancer that reduces the production or effect of androgen hormones, eg. testosterone, which many prostate cancers depend on. The side-effects make it controversial in some cases. There is an increased risk of osteoporosis, and possibly ...
But if my goal was to avoid hormone therapy side effects for as long as possible—recognizing the inherent risks—then it may make sense to delay therapy. To be honest, I’m not sure where on that spectrum I want to land. We wrapped up the meeting, coming to a consensus that: We’...
Androgen deprivation therapy (ADT) is an effective hormonal therapy for treating early stages of prostate cancer. The lowering or preventing androgen hormones (testosterone and dihydrotestosterone) from entering into the prostate cells have shown to shrink or slow the growth of the malignant cells. Sev...
Options include injected and oral medications, or surgery to remove those parts of the testicles that produce testosterone. Androgen deprivation therapy may produce side effects.DOI: http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/P ...
The therapeutic effects and side effects of androgen deprivation therapy (ADT), which is a main treatment method for metastatic prostate cancer, are well k... S Min,Choi,S Chul,... - 《Korean Journal of Urology》 被引量: 6发表: 2015年 Late Radiation and Cardiovascular Adverse Effects After...
Androgendeprivation therapy (ADT) is common in many stages of prostate cancer therapy.9,10Unfortunately, ADT is associated with a substantial decrease in BMD, which increases with the duration of therapy.11It is not uncommon for patients on ADT to have BMD losses of 3–5% per year, up to ...
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. The current trends in favor of androgen deprivation therapy (ADT) for nonmetastatic prostate cancer at the stage of biochemical recurrence or increasing pr... CS Higano - 《Urology》 被引量: 395发表: 2003年 Hormone...
The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival than bicalutamide (BIC)-ADT. Accordin...
This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy. 展开 ...